Medicare Enrolled
Dr. Michael Benjamin, M.D.
Hematology & Oncology · West Hills, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Benjamin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Benjamin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Benjamin
Dr. Michael Benjamin is a hematology & oncology specialist in West Hills, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Benjamin performed 48,984 Medicare services across 1,642 unique beneficiaries.
Between the years covered by Open Payments, Dr. Benjamin received a total of $17,744 from 71 pharmaceutical and/or device companies across 607 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Benjamin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 15% volume in CA
$17,744 industry payments
Medicare Practice Summary
Medicare Utilization ↗48,984
Medicare services
Top 15% in CA for hematology & oncology
1,642
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,578 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
25,504 | $1 | $3 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
7,781 | $6 | $21 |
| Denosumab injection (Prolia/Xgeva) | 3,960 | $19 | $29 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,670 | $0 | $0 |
| Injection, granisetron hydrochloride, 100 mcg | 2,453 | $0 | $1 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,222 | $74 | $158 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
868 | $12 | $55 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
740 | $26 | $71 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
682 | $18 | $48 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
459 | $99 | $206 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
335 | $14 | $50 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
313 | $56 | $165 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
298 | $103 | $231 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
255 | $1 | $2 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
253 | $119 | $420 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
188 | $1 | $1 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
167 | $25 | $68 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
151 | $146 | $305 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
144 | $46 | $96 |
| Venipuncture for blood draw Insertion of a needle into a vein to collect blood samples. This procedure is performed on patients aged 3 years or older. |
137 | $15 | $33 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
96 | $66 | $172 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
89 | $145 | $379 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
82 | $59 | $157 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
45 | $87 | $232 |
| New patient office visit, complex (60-74 min) | 33 | $185 | $406 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
30 | $121 | $332 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
29 | $28 | $73 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
56.7% high complexity
38.0% medium
5.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,744
Total received (2018-2024)
Avg $2,535/year across 7 years
Top 23% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
71
Companies
607
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,388 (81.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,397 (13.5%)
Other
Charitable contributions, space rental, and other categories
$959 (5.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,611
2023
$2,585
2022
$1,535
2021
$1,865
2020
$1,650
2019
$2,220
2018
$5,278
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$461
PFIZER INC.
$329
Amgen Inc.
$239
AstraZeneca Pharmaceuticals LP
$211
Daiichi Sankyo Inc.
$153
Gilead Sciences, Inc.
$149
Genentech USA, Inc.
$117
Incyte Corporation
$97
E.R. Squibb & Sons, L.L.C.
$81
Astellas Pharma US Inc
$77
Janssen Biotech, Inc.
$74
ABBVIE INC.
$62
Agios Pharmaceuticals, Inc.
$54
Eisai Inc.
$51
Merck Sharp & Dohme LLC
$50
PharmaEssentia USA Corporation
$50
ARRAY BIOPHARMA INC
$49
Adaptive Biotechnologies Corporation
$45
Lilly USA, LLC
$42
Celgene Corporation
$35
EMD Serono, Inc.
$35
PUMA BIOTECHNOLOGY, INC.
$28
Mirati Therapeutics, Inc.
$23
Novocure Inc.
$22
Takeda Pharmaceuticals U.S.A., Inc.
$21
Azurity Pharmaceuticals, Inc.
$20
Octapharma USA, Inc.
$18
Legend Biotech USA Inc.
$17
Top 3 companies account for 39.4% of 2024 payments
All-time payments by company (2018-2024) ›
Takeda Pharmaceuticals U.S.A., Inc.
$3,035
Amgen Inc.
$1,229
AstraZeneca Pharmaceuticals LP
$1,017
PFIZER INC.
$975
Novartis Pharmaceuticals Corporation
$971
Janssen Biotech, Inc.
$859
Genentech USA, Inc.
$737
GENZYME CORPORATION
$678
E.R. Squibb & Sons, L.L.C.
$655
Incyte Corporation
$485
Merck Sharp & Dohme Corporation
$384
Astellas Pharma US Inc
$321
Merck Sharp & Dohme LLC
$318
Eisai Inc.
$303
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Lilly USA, LLC
$282
Karyopharm Therapeutics Inc.
$280
Gilead Sciences, Inc.
$276
Seagen Inc.
$276
GlaxoSmithKline, LLC.
$270
Celgene Corporation
$269
Daiichi Sankyo Inc.
$257
PORTOLA PHARMACEUTICALS, INC.
$247
Seattle Genetics, Inc.
$219
Janssen Pharmaceuticals, Inc
$214
TESARO, Inc.
$201
EMD Serono, Inc.
$190
BeiGene USA, Inc.
$184
Alexion Pharmaceuticals, Inc.
$172
ADC Therapeutics America, Inc.
$158
Array BioPharma Inc.
$133
Kite Pharma, Inc.
$130
Octapharma USA, Inc.
$120
Puma Biotechnology, Inc.
$100
Bayer HealthCare Pharmaceuticals Inc.
$96
Boehringer Ingelheim Pharmaceuticals, Inc.
$92
PUMA BIOTECHNOLOGY, INC.
$88
Rigel Pharmaceuticals, Inc.
$79
PharmaEssentia USA Corporation
$77
Mirati Therapeutics, Inc.
$75
ABBVIE INC.
$75
Cardinal Health 108 LLC
$65
Agios Pharmaceuticals, Inc.
$54
Clovis Oncology, Inc.
$51
ARRAY BIOPHARMA INC
$49
Bayer Healthcare Pharmaceuticals Inc.
$48
Adaptive Biotechnologies Corporation
$45
Blueprint Medicines Corporation
$44
Epizyme, Inc.,
$40
Helsinn Therapeutics (U.S.), Inc.
$35
EUSA Pharma (US) LLC
$34
Teva Pharmaceuticals USA, Inc.
$30
GE HEALTHCARE
$30
Pharmacyclics LLC, An AbbVie Company
$29
GE HealthCare
$29
Tactile Systems Technology Inc
$28
Regeneron Healthcare Solutions, Inc.
$26
CSL Behring
$25
TOLMAR Pharmaceuticals, Inc.
$23
Novocure Inc.
$22
MEDIVATION FIELD SOLUTIONS LLC
$21
Dendreon Pharmaceuticals LLC
$21
Foundation Medicine, Inc.
$21
ViiV Healthcare Company
$21
Taiho Oncology, Inc.
$21
Azurity Pharmaceuticals, Inc.
$20
Secura Bio, Inc.
$19
AbbVie Inc.
$19
Legend Biotech USA Inc.
$17
Tolmar, Inc.
$15
EISAI INC.
$14
Top 3 companies account for 29.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · ANDEXXA · APRETUDE · AYVAKIT · Abraxane · Alecensa · Avastin · BAVENCIO · BENDEKA · BESREMI · BEVYXXA · BOSULIF · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CALQUENCE · CUTAQUIG · CYRAMZA · DARZALEX · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERLEADA · Enhertu · FARYDAK · FLEXITOUCH · Fabhalta · GAUCHER-DISEASE · GAVRETO · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INLYTA · Idelvion · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · Optune Lua (NovoTTF-200T) · PANZYGA · PEMAZYRE · PLUVICTO · PROVENGE · PYRUKYND · Pomalyst · REBLOZYL · RETACRIT · RETEVMO · RYBREVANT · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SPRYCEL · SUTENT · Soliris · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VIVIMUSTA · VOTRIENT · Venclexta · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · ZEJULA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (81%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
251
Per 100K population
2.5
County median income
$87,760
Nearest hospital
UCLA WEST VALLEY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Benjamin is a mixed practice specialist, with above-average Medicare volume (top 15% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Benjamin experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Benjamin performed 25,504 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Benjamin receive payments from pharmaceutical companies?
Yes. Dr. Benjamin received a total of $17,744 from 71 companies across 607 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Benjamin's costs compare to other hematology & oncology specialists in West Hills?
Dr. Benjamin's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Benjamin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in West Hills
Browse hematology & oncology specialists in West Hills ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology